RR001 + nab-paclitaxel + gemcitabine

**RR001 + nab-paclitaxel + gemcitabine** is a combination regimen comprising RRx-001 (1-bromoacetyl-3,3-dinitroazetidine), an investigational small molecule with multifaceted antitumor mechanisms; nab-paclitaxel (albumin-bound paclitaxel), a nanoparticle formulation of the microtubule inhibitor paclitaxel; and gemcitabine, a cytidine analog chemotherapeutic agent. RRx-001 exerts anti-cancer activity by downregulating CD47, upregulating TP53, inhibiting NLRP3 inflammasome, inducing Nrf2 signaling, mediating epigenetic modulation, normalizing tumor vasculature, reprogramming tumor-associated macrophages, generating reactive oxygen/nitrogen species, and releasing nitric oxide in hypoxic/inflamed tissues[1][3][7]. Nab-paclitaxel interferes with microtubule function, inhibiting cell division, while gemcitabine inhibits DNA synthesis, interfering with cell proliferation[4][6][8]. The combination is investigated for advanced solid tumors, particularly **pancreatic cancer**, seeking to leverage synergistic anti-tumor effects and improve therapeutic outcomes versus standard doublet therapies[2][4][6][8].

Other names

RRx-001RRx001RRx 001albumin-bound paclitaxelpaclitaxel protein-boundgemcitabine hydrochloride